Nov. 9 Media Roundup
A few of our favorite stories last week included some great news on the mHealth and Big Data front, a smart medicine bottle that reminds patients to take prescriptions and an exoskeleton being developed for paralyzed patients.
mHealth and Tech
- Powerful cloud-based computers can crunch medical records and may be able to prevent painful, expensive health issues by forecasting your future health.
- It looks like the digital health field isn’t suffering from too much hype. A new survey found that patients need more access to and knowledge of digital health communication tools.
- There are a bunch of reasons that smart entrepreneurs are focusing on womens’ health, including a steady rise in funding since 2011.
- A new article suggests that wearable devices will drive value in clinical trials. Among other reasons, the potential of a constant data stream is continuing to draw attention.
- Last year the Big Data sector grew 40 percent. But will personal health data be used for good or will it become dangerous to patients?
- Healthcare VC firm Frazier Healthcare Partners just closed their eighth fund after raising $262 million. They believe “looking for companies addressing an unmet need” is a key to their success.
- A new, ultrathin wearable device relying on tiny heat sensors has been developed and can measure blood flow.
- Ever wonder exactly how Big Data will drive precision medicine? David Shaywitz talks about it in the context of a diabetes study on Forbes.
Pharma and Life Science
- Can a focus on patient diversity improve participation in clinical trials? Given that 90 percent of adults own a cell phone, technology is increasingly seen as a means to recruit diverse demographic groups.
- A liquid biopsy may offer a non-invasive alternative technique to impact cancer treatments.
- Swiss scientists are working to develop a new exoskeleton for paralyzed and disabled patients. It may eventually allow these patients the ability to turn and climb.
- What a great idea! A smart pill bottle being made by AdhereTech claims to have the the “whole package” and has adherence rates up by 20 percent.
- Ultragenyx and Arcturus have joined forces to fight rare diseases using messenger RNA therapeutics.
- Did you know that the 21st Century Cares Act modernizes and streamlines FDA approvals? A great article highlights five key takeaways about it.